Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Diabetic Nephropathy | Research article

Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways

Authors: Lan Yao, Jie Li, Linlin Li, Xinxia Li, Rui Zhang, Yujie Zhang, Xinmin Mao

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Coreopsis tinctoria Nutt is an ethnomedicine widely used in Xinjiang, China. It is consumed as a herbal tea by local Uyghur people to treat high blood pressure and diarrhea. Our previous study confirmed that the ethyl acetate extract of Coreopsis tinctoria (AC) had a protective effect on diabetic nephropathy (DN) in an in vivo experiment. Here we aim to elucidate the protective mechanism of AC and marein, the main ingredient in Coreopsis tinctoria on renal fibrosis and inflammation in vitro under high glucose (HG) conditions.

Methods

A HG-induced barrier dysfunction model in rat mesangial cells (HBZY-1) was established. The cells were exposed to AC and marein and/or HG for 24 h. Then, the renal protective effects of AC and marein via transforming growth factor-β1 (TGF-β1)/Smads, AMP-activated kinase protein (AMPK), and nuclear factor kappa beta (NF-κB) signaling were assessed.

Results

Both AC and marein suppressed rat mesangial cell hyperplasia and significantly attenuated the expression of HG-disrupted fibrotic and inflammatory proteins in HBZY-1 cells. It was also confirmed that AC and marein remarkably attenuated HG-induced renal inflammation and fibrosis by regulating the AMPK, TGF-β1/Smads, and NF-κB signaling pathways.

Conclusion

These results indicated that AC and marein may delay the progression of DN, at least in part, by suppressing HG-induced renal inflammation and fibrosis. Marein may be one of the bioactive compounds in AC.
Literature
1.
go back to reference Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37:2864–83.CrossRef Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37:2864–83.CrossRef
2.
go back to reference Sharma D, Bhattacharya P, Kalia K, Tiwari V. Diabetic nephropathy. New insights into established therapeutic paradigms and novel molecular targets. Diabetes Res Clin Pract. 2017;128:91–108.CrossRef Sharma D, Bhattacharya P, Kalia K, Tiwari V. Diabetic nephropathy. New insights into established therapeutic paradigms and novel molecular targets. Diabetes Res Clin Pract. 2017;128:91–108.CrossRef
3.
go back to reference Iwai T, Miyazaki M, Yamada G, Nakayama M, Yamamoto T, Satoh M, et al. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study. Clin Exp Nephrol. 2017;27:1451–4. Iwai T, Miyazaki M, Yamada G, Nakayama M, Yamamoto T, Satoh M, et al. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study. Clin Exp Nephrol. 2017;27:1451–4.
4.
go back to reference Alrawahi AH, Rizvi SG, Al-Riyami D, Al-Anqoodi Z. Prevalence and risk factors of diabetic nephropathy in omani type-2 diabetics in Al-dakhiliyah region. Oman Med J. 2012;27:212–6.CrossRef Alrawahi AH, Rizvi SG, Al-Riyami D, Al-Anqoodi Z. Prevalence and risk factors of diabetic nephropathy in omani type-2 diabetics in Al-dakhiliyah region. Oman Med J. 2012;27:212–6.CrossRef
5.
go back to reference Lu B, Wen J, Song XY, Dong XH, Yang YH, Zhang ZY. High prevalence of albuminuria in population-based patients diagnosed with type-2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract. 2007;75:184–92.CrossRef Lu B, Wen J, Song XY, Dong XH, Yang YH, Zhang ZY. High prevalence of albuminuria in population-based patients diagnosed with type-2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract. 2007;75:184–92.CrossRef
6.
go back to reference Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol. 2012;771:35–41.PubMed Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol. 2012;771:35–41.PubMed
7.
go back to reference Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;15:30–3.CrossRef Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;15:30–3.CrossRef
8.
go back to reference Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med. 2012;27:458–68.CrossRef Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med. 2012;27:458–68.CrossRef
9.
go back to reference Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant. 2000;15:1900–2.CrossRef Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant. 2000;15:1900–2.CrossRef
10.
go back to reference Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med. 2017;32:11–25.CrossRef Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med. 2017;32:11–25.CrossRef
11.
go back to reference Garcia-Garcia PM, Getino-Melian MA, Dominguez-Pimentel V, Navarro-Gonzalez JF. Inflammation in diabetic kidney disease. World J Diabetes. 2014;5:431–43.CrossRef Garcia-Garcia PM, Getino-Melian MA, Dominguez-Pimentel V, Navarro-Gonzalez JF. Inflammation in diabetic kidney disease. World J Diabetes. 2014;5:431–43.CrossRef
12.
go back to reference Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294:697–701.CrossRef Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294:697–701.CrossRef
13.
go back to reference Lan Y, Zhou Q, Wu ZL, NF-kappa B. Involved in transcription enhancement of TGF-beta 1 induced by ox-LDL in rat mesangial cells. Chin Med J. 2004;117:225–30.PubMed Lan Y, Zhou Q, Wu ZL, NF-kappa B. Involved in transcription enhancement of TGF-beta 1 induced by ox-LDL in rat mesangial cells. Chin Med J. 2004;117:225–30.PubMed
14.
go back to reference Meng XM, Tang PM, Li J, Lan HY. TGF-β/Smad signaling in renal fibrosis. Front Physiol. 2015;19:82–8. Meng XM, Tang PM, Li J, Lan HY. TGF-β/Smad signaling in renal fibrosis. Front Physiol. 2015;19:82–8.
15.
go back to reference Zhang B, Shi YQ, Zou JJ, Chen XF, Tang W, Ye F, et al. High glucose stimulates cell proliferation and collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling. Int Urol Nephrol. 2017;49:2079–86.CrossRef Zhang B, Shi YQ, Zou JJ, Chen XF, Tang W, Ye F, et al. High glucose stimulates cell proliferation and collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling. Int Urol Nephrol. 2017;49:2079–86.CrossRef
16.
go back to reference Xiao Y, Liu Y, Yu K, Zhou L, Bi J, Cheng J, et al. The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2013;2013:937549.PubMedPubMedCentral Xiao Y, Liu Y, Yu K, Zhou L, Bi J, Cheng J, et al. The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2013;2013:937549.PubMedPubMedCentral
17.
go back to reference Sun GD, Li CY, Cui WP, Guo QY, Dong CQ, Zou HB, et al. Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy. J Diabetes Res. 2016;5749857:2016. Sun GD, Li CY, Cui WP, Guo QY, Dong CQ, Zou HB, et al. Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy. J Diabetes Res. 2016;5749857:2016.
18.
go back to reference Li Y, Chen X, Xue J, Liu J, Chen X, Wulasihan M. Flavonoids furom Coreopsis tinctoria adjust lipid metabolism in hyperlipidemia animals by down-regulating adipose differentiation-related protein. Lipids Health Dis. 2014;13:193–211.CrossRef Li Y, Chen X, Xue J, Liu J, Chen X, Wulasihan M. Flavonoids furom Coreopsis tinctoria adjust lipid metabolism in hyperlipidemia animals by down-regulating adipose differentiation-related protein. Lipids Health Dis. 2014;13:193–211.CrossRef
19.
go back to reference Wang W, Chen W, Yang Y, Liu T, Yang H, Xin Z. New phenolic compounds from Coreopsis tinctoria Nutt and their antioxidant and angiotensin i-converting enzyme inhibitory activities. J Agric Food Chem. 2015;63:200–7.CrossRef Wang W, Chen W, Yang Y, Liu T, Yang H, Xin Z. New phenolic compounds from Coreopsis tinctoria Nutt and their antioxidant and angiotensin i-converting enzyme inhibitory activities. J Agric Food Chem. 2015;63:200–7.CrossRef
20.
go back to reference Dias T, Bronze MR, Houghton PJ, Mota-Filipe H, Paulo A. The flavonoid-rich fraction of Coreopsis tinctoria promotes glucose tolerance regain through pancreatic function recovery in streptozotocin-induced glucose-intolerant rats. J Ethnopharmacol. 2010;132:483–90.CrossRef Dias T, Bronze MR, Houghton PJ, Mota-Filipe H, Paulo A. The flavonoid-rich fraction of Coreopsis tinctoria promotes glucose tolerance regain through pancreatic function recovery in streptozotocin-induced glucose-intolerant rats. J Ethnopharmacol. 2010;132:483–90.CrossRef
21.
go back to reference Zhang Y, Shi S, Zhao M, Chai X, Coreosides TP. A-D, C14-polyacetylene glycosides from the capitula of Coreopsis tinctoria and its anti-inflammatory activity against COX-2. Fitoterapia. 2013;87:93–7.CrossRef Zhang Y, Shi S, Zhao M, Chai X, Coreosides TP. A-D, C14-polyacetylene glycosides from the capitula of Coreopsis tinctoria and its anti-inflammatory activity against COX-2. Fitoterapia. 2013;87:93–7.CrossRef
22.
go back to reference Chen LX, Hu D, Lam SC, Ge L, Wu D, Zhao J, et al. Comparison of antioxidant activities of different parts from snow chrysanthemum (Coreopsis tinctoria Nutt.) and identification of their natural antioxidants using high performance liquid chromatography coupled with diode array detection and mass spectrometry and 2,2′-azinobis(3-ethylbenzthiazoline-sulfonic acid)diammonium salt-based assay. J Chromatogr A. 2016;1428:134–42.CrossRef Chen LX, Hu D, Lam SC, Ge L, Wu D, Zhao J, et al. Comparison of antioxidant activities of different parts from snow chrysanthemum (Coreopsis tinctoria Nutt.) and identification of their natural antioxidants using high performance liquid chromatography coupled with diode array detection and mass spectrometry and 2,2′-azinobis(3-ethylbenzthiazoline-sulfonic acid)diammonium salt-based assay. J Chromatogr A. 2016;1428:134–42.CrossRef
23.
go back to reference Yao L, Li L, Li X, Li H, Zhang Y, Zhang R, et al. The anti-inflammatory and anti-fibrotic effects of Coreopsis tinctoria Nutt on high-glucose-fat diet and streptozotocin-induced diabetic renal damage in rat. BMC Complement Altern Med. 2015;15:314.CrossRef Yao L, Li L, Li X, Li H, Zhang Y, Zhang R, et al. The anti-inflammatory and anti-fibrotic effects of Coreopsis tinctoria Nutt on high-glucose-fat diet and streptozotocin-induced diabetic renal damage in rat. BMC Complement Altern Med. 2015;15:314.CrossRef
24.
go back to reference Xie X, Peng J, Chang X, Huang K, Huang J, Wang S, et al. Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol. 2013;369:86–97.CrossRef Xie X, Peng J, Chang X, Huang K, Huang J, Wang S, et al. Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol. 2013;369:86–97.CrossRef
25.
go back to reference Yokoyama H, Deckert T. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med. 1996;13:313–20.CrossRef Yokoyama H, Deckert T. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med. 1996;13:313–20.CrossRef
26.
go back to reference Lan T, Liu W, Xie X, Huang K, Peng J, Huang J, et al. Berberine suppresses high glucose-induced TGF-β1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway. Eur J Pharmacol. 2012;697:165–72.CrossRef Lan T, Liu W, Xie X, Huang K, Peng J, Huang J, et al. Berberine suppresses high glucose-induced TGF-β1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway. Eur J Pharmacol. 2012;697:165–72.CrossRef
27.
go back to reference Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 1998;54:1390–1.CrossRef Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 1998;54:1390–1.CrossRef
28.
go back to reference Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci. 2011;7:1056–67.CrossRef Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci. 2011;7:1056–67.CrossRef
29.
go back to reference Goldfarb S, Ziyadeh FN. TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc. 2001;112:27–32 discussion 33.PubMedPubMedCentral Goldfarb S, Ziyadeh FN. TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc. 2001;112:27–32 discussion 33.PubMedPubMedCentral
30.
go back to reference Zhao J, Miyamoto S, You YH, Sharma K. AMP-activated protein kinase (AMPK) activation inhibits nuclear translocation of Smad4 in mesangial cells and diabetic kidneys. Am J Physiol Renal Physiol. 2014;308:F1167–77.CrossRef Zhao J, Miyamoto S, You YH, Sharma K. AMP-activated protein kinase (AMPK) activation inhibits nuclear translocation of Smad4 in mesangial cells and diabetic kidneys. Am J Physiol Renal Physiol. 2014;308:F1167–77.CrossRef
31.
go back to reference Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes. 2014;5:393–8.CrossRef Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes. 2014;5:393–8.CrossRef
32.
go back to reference Crunkhorn S. Metabolic disorders: breaking the links between inflammation and diabetes. Nat Rev Drug Discov. 2013;12:205–16. Crunkhorn S. Metabolic disorders: breaking the links between inflammation and diabetes. Nat Rev Drug Discov. 2013;12:205–16.
33.
go back to reference Ahmad S, Ullah F, Zeb A, Ayaz M, Ullah F, Sadiq A. Evaluation of Rumex hastatus D. Don for cytotoxic potential against HeLa and NIH/3T3 cell lines: chemical characterization of chloroform fraction and identification of bioactive compounds. BMC Complement Altern Med. 2016;16:308.CrossRef Ahmad S, Ullah F, Zeb A, Ayaz M, Ullah F, Sadiq A. Evaluation of Rumex hastatus D. Don for cytotoxic potential against HeLa and NIH/3T3 cell lines: chemical characterization of chloroform fraction and identification of bioactive compounds. BMC Complement Altern Med. 2016;16:308.CrossRef
34.
go back to reference Ayaz M, Junaid M, Ullah F, Sadiq A, Subhan F, Khan MA, et al. Molecularly characterized solvent extracts and Saponins from Polygonum hydropiper L. show high anti-Angiogenic, anti-tumor, brine shrimp, and fibroblast NIH/3T3 cell line cytotoxicity. Front Pharmacol. 2016;7:74.CrossRef Ayaz M, Junaid M, Ullah F, Sadiq A, Subhan F, Khan MA, et al. Molecularly characterized solvent extracts and Saponins from Polygonum hydropiper L. show high anti-Angiogenic, anti-tumor, brine shrimp, and fibroblast NIH/3T3 cell line cytotoxicity. Front Pharmacol. 2016;7:74.CrossRef
35.
go back to reference Ayaz M, Junaid M, Ullah F, Subhan F, Sadiq A, Ali G, et al. Anti-Alzheimer's studies on β-Sitosterol isolated from Polygonum hydropiper L. Front Pharmacol. 2017;8:697.CrossRef Ayaz M, Junaid M, Ullah F, Subhan F, Sadiq A, Ali G, et al. Anti-Alzheimer's studies on β-Sitosterol isolated from Polygonum hydropiper L. Front Pharmacol. 2017;8:697.CrossRef
36.
go back to reference Heerspink HJ, de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud. 2011;8:392–402.CrossRef Heerspink HJ, de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud. 2011;8:392–402.CrossRef
37.
go back to reference Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-κB and MAPK signal pathways. J Mol Histol. 2015;46:283–90.CrossRef Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-κB and MAPK signal pathways. J Mol Histol. 2015;46:283–90.CrossRef
38.
go back to reference Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745–54.CrossRef Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745–54.CrossRef
39.
go back to reference Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38.CrossRef Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38.CrossRef
40.
go back to reference Hallows KR, Mount PF, Pastor-Soler NM, Power DA. Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol. 2010;298:1067–77.CrossRef Hallows KR, Mount PF, Pastor-Soler NM, Power DA. Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol. 2010;298:1067–77.CrossRef
41.
go back to reference Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62.CrossRef Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62.CrossRef
42.
go back to reference Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2002;2:28.CrossRef Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2002;2:28.CrossRef
43.
go back to reference Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444–52.CrossRef Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444–52.CrossRef
44.
go back to reference Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:617–27.CrossRef Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:617–27.CrossRef
45.
go back to reference Kim Y, Park CW. Adenosine monophosphate-activated protein kinase in diabetic nephropathy. Kidney Res Clin Pract. 2016;35:69–77.CrossRef Kim Y, Park CW. Adenosine monophosphate-activated protein kinase in diabetic nephropathy. Kidney Res Clin Pract. 2016;35:69–77.CrossRef
46.
go back to reference Khan M, Siddiqui N. Metformin use in renal disease. J Pak Med Assoc. 2017;68:1301. Khan M, Siddiqui N. Metformin use in renal disease. J Pak Med Assoc. 2017;68:1301.
47.
go back to reference Imam TH. Changes in metformin use in chronic kidney disease. Clin Kidney J. 2017;10:301–4.CrossRef Imam TH. Changes in metformin use in chronic kidney disease. Clin Kidney J. 2017;10:301–4.CrossRef
48.
go back to reference Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. PLoS One. 2014;9:e88087.CrossRef Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. PLoS One. 2014;9:e88087.CrossRef
49.
go back to reference Kitada M, Ogura Y, Monno I, Koya D. Regulating autophagy as a therapeutic target for diabetic nephropathy. Curr Diab Rep. 2017;17:53.CrossRef Kitada M, Ogura Y, Monno I, Koya D. Regulating autophagy as a therapeutic target for diabetic nephropathy. Curr Diab Rep. 2017;17:53.CrossRef
50.
go back to reference Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–42.CrossRef Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–42.CrossRef
51.
go back to reference Pichler R, Afkarian M, Dieter BP, Tuttle KR. Inflammation and inflammatory mediators in kidney disease. Am J Physiol Renal Physiol. 2016;312:716–31.CrossRef Pichler R, Afkarian M, Dieter BP, Tuttle KR. Inflammation and inflammatory mediators in kidney disease. Am J Physiol Renal Physiol. 2016;312:716–31.CrossRef
52.
go back to reference Zheng Z, Zheng F. Immune cells and inflammation in diabetic nephropathy. J Diabetes Res. 2016;2016:1–10. Zheng Z, Zheng F. Immune cells and inflammation in diabetic nephropathy. J Diabetes Res. 2016;2016:1–10.
53.
go back to reference Tesch GH, Lim AK. Inflammation in diabetic nephropathy. Mediat Inflamm. 2012;2012. Tesch GH, Lim AK. Inflammation in diabetic nephropathy. Mediat Inflamm. 2012;2012.
54.
go back to reference Gnudi L. A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages? Nephrol Dial Transplant. 2015;30:525–57.CrossRef Gnudi L. A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages? Nephrol Dial Transplant. 2015;30:525–57.CrossRef
55.
go back to reference Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis. 1996;27:640–6.CrossRef Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis. 1996;27:640–6.CrossRef
56.
go back to reference Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116–28.CrossRef Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116–28.CrossRef
57.
go back to reference Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006;69:73–80.CrossRef Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006;69:73–80.CrossRef
58.
go back to reference Tesch GH. Diabetic nephropathy – is this an immune disorder? Clin Sci (Lond). 2017;131:2183–99.CrossRef Tesch GH. Diabetic nephropathy – is this an immune disorder? Clin Sci (Lond). 2017;131:2183–99.CrossRef
59.
go back to reference Patel S, Santani D. Role of NF-kB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep. 2009;61:595–603.CrossRef Patel S, Santani D. Role of NF-kB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep. 2009;61:595–603.CrossRef
Metadata
Title
Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways
Authors
Lan Yao
Jie Li
Linlin Li
Xinxia Li
Rui Zhang
Yujie Zhang
Xinmin Mao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-018-2410-7

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue